Zardi L - Search Results

1

Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin.

Matter CM, Schuler PK, Alessi P, Meier P, Ricci R, Zhang D, Halin C, Castellani P, Zardi L, Hofer CK, Montani M, Neri D, Lüscher TF. Matter CM, et al. Among authors: zardi l. Circ Res. 2004 Dec 10;95(12):1225-33. doi: 10.1161/01.RES.0000150373.15149.ff. Epub 2004 Nov 11. Circ Res. 2004. PMID: 15539632

2

Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins.

Halin C, Niesner U, Villani ME, Zardi L, Neri D. Halin C, et al. Among authors: zardi l. Int J Cancer. 2002 Nov 10;102(2):109-16. doi: 10.1002/ijc.10674. Int J Cancer. 2002. PMID: 12385005

3

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

Castellani P, Borsi L, Carnemolla B, Birò A, Dorcaratto A, Viale GL, Neri D, Zardi L. Castellani P, et al. Among authors: zardi l. Am J Pathol. 2002 Nov;161(5):1695-700. doi: 10.1016/S0002-9440(10)64446-X. Am J Pathol. 2002. PMID: 12414516 Free PMC article.

4

An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance.

Melkko S, Halin C, Borsi L, Zardi L, Neri D. Melkko S, et al. Among authors: zardi l. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1485-90. doi: 10.1016/s0360-3016(02)03927-5. Int J Radiat Oncol Biol Phys. 2002. PMID: 12459375

5

Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.

Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D. Halin C, et al. Among authors: zardi l. Cancer Res. 2003 Jun 15;63(12):3202-10. Cancer Res. 2003. PMID: 12810649

6

Fibronectin as target for tumor therapy.

Kaspar M, Zardi L, Neri D. Kaspar M, et al. Among authors: zardi l. Int J Cancer. 2006 Mar 15;118(6):1331-9. doi: 10.1002/ijc.21677. Int J Cancer. 2006. PMID: 16381025 Review.

7

Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides.

Niesner U, Halin C, Lozzi L, Günthert M, Neri P, Wunderli-Allenspach H, Zardi L, Neri D. Niesner U, et al. Among authors: zardi l. Bioconjug Chem. 2002 Jul-Aug;13(4):729-36. doi: 10.1021/bc025517+. Bioconjug Chem. 2002. PMID: 12121127

8

Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer.

Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P. Santimaria M, et al. Among authors: zardi l. Clin Cancer Res. 2003 Feb;9(2):571-9. Clin Cancer Res. 2003. PMID: 12576420

9

Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy.

Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H, Zardi L, Neri D. Ebbinghaus C, et al. Among authors: zardi l. Int J Cancer. 2005 Aug 20;116(2):304-13. doi: 10.1002/ijc.20952. Int J Cancer. 2005. PMID: 15800913

10

Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo.

Silacci M, Brack SS, Späth N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D. Silacci M, et al. Among authors: zardi l. Protein Eng Des Sel. 2006 Oct;19(10):471-8. doi: 10.1093/protein/gzl033. Epub 2006 Aug 22. Protein Eng Des Sel. 2006. PMID: 16928692 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

199 results

Search Page

Filters